Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas

Trial Profile

A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas

Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2018

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Adenocarcinoma; Insulin resistance; Pancreatic cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 May 2018 Status changed from recruiting to completed.
    • 06 Jun 2017 Primary endpoint (Adiponectin levels) has been met as per the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top